Navigation Links
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Date:11/16/2007

U.S. Food, Drug & Cosmetic Act (FDCA) allows the Food and Drug Administration (FDA) to approve a follow-on drug on the basis of data in the scientific literature or conclusions regarding safety or effectiveness made by the FDA in the approval of other drugs. This regulatory pathway potentially makes it easier for drug manufacturers to obtain rapid approval of new forms of drugs based on the FDA's approval of the original drug. Some examples of products that may be allowed to follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication. Upon approval, a drug may be marketed only for the FDA-approved indications in the approved dosage forms. Further clinical trials are necessary to gain approval for the use of the product for any additional indications or dosage forms. To the extent a Section 505(b)(2) applicant is relying on the FDA's findings for an already-approved drug, the applicant is required to certify to the FDA concerning any patents listed for the approved drug in the FDA's Orange Book publication, which may include a certification that listed patents are invalid or will not be infringed by the manufacture, use or sale of the new drug.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
8. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)... to Have Higher Sensitivity and Specificity, than...was the preferred test in all phas... 13 /- AT First Diagnostic LLC an,eme...ic test kits, today,announced that a recent evalua...f Research of the FirstVue(TM) HBSAG Test, was rel...
(Date:10/13/2008)...- Facet Solutions, Inc. today,announc...nts from its US,IDE Pilot Study. The results show ... scores, and an 80% reduction in Visual Analog Sco...resident & CEO for Facet Solutions,added, "We are... far not,only demonstrate significant pain relief ...
(Date:10/12/2008)...N, Oct. 12 /- Boston,Scient...ults from an analysis,of nearly 7,500 patients fro...esigned to confirm the performance of the TAXUS(R)...stem in real-world practice. The,two-year pooled A...nical,restenosis in patients with diabetes as effe...
(Date:10/10/2008)...is Treatment with Kogenate FS Reduces the,Risk of ...No Pre-Existing,Joint Damage, BERKELEY, Calif., O...ced today that the U.S. Food and Drug Administrati...enate(R) FS Antihemophilic Factor,(Recombinant) to... risk of,joint damage in patients aged 0-16 years ...
Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5Shingles Pain Treatment Will Benefit More Patients 2872 1Shingles Pain Treatment Will Benefit More Patients 2872 2Shingles Pain Treatment Will Benefit More Patients 2872 3Shingles Pain Treatment Will Benefit More Patients 2872 4Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 1Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 3Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 1Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 21New Health Knowledge Base and Semantic Search Engine Announced 25637 1New Health Knowledge Base and Semantic Search Engine Announced 25637 2
...d Insurance Coverage Varies,Greatly for Different ... 2007-- Most U.S. adults support,approving the use...act people,s quality of life, including birth cont...reat erectile,dysfunction and improve memory and t...ieve these types of treatments should be covered,b...
...y 1, 2007 - Progenics,Pharmaceuticals, Inc. (NASDA... first clinical trial of its investigational drug,...mmunodeficiency,virus (HIV), the causative agent o... of PRO 140 achieved an average maximum,decrease o...,log10), with individual reductions ranging up to ...
Other Medicine Technology:Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 2Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 3Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 2Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 3Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 5Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 6Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 7
(Date:10/13/2008)...ges Latinos to Get Tested, LOS ANGELES, Oct. 13 /...half of all newly diagnosed HIV/AIDS cases,reporte...ionally., -- A week of activities aimed at raisin...ting to coincide with National Latino AIDS Awarene...r Community, Our Responsibility: Latinos in Action...
(Date:10/13/2008)...n ever before, study finds , , MONDAY,...ver are being treated for high blood pressure, say...nd Blood Institute. , The major factor in the d...igh blood pressure appears to be the obesity epide...dditional efforts are needed to prevent hypertensi...
(Date:10/13/2008)...g advances study Study needed because of low... 13 /PRNewswire/ -- Advanced Circulatory Systems, ...ced today that it has received,an additional $1.5 ...,Health (NIH) to continue a study testing two devi...rdiac arrest outside a hospital. Parts of Oakland,...
(Date:10/13/2008)...valve.com ) announced today that the expanded clin...aneous aortic valve replacement (PAVR) in high-ris...l patients at an accelerating pace. More than 1,80...ly 100 centers in 20 countries. , ...er 13, 2008 -- During the Monday Transcatheter Ao...
Breaking Medicine News(10 mins):Health News:Nearly Half of Newly Diagnosed HIV/AIDS Cases in Los Angeles County Are Among Latinos 2Health News:Blood Pressure on the Rise in America 2Health News:Blood Pressure on the Rise in America 3Health News:3 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Health News: CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) : Highly encouraging registry data also presented at TCT 2008 2
...ofi-Aventis, one of the world's leading pharmaceut... Taxotere (docetaxel) improves survival in patient... clinical trial named TAX 327 compared Taxotere pl...one) plus prednisone. The study included a little ...
...nagers who use mobile phones for many hours a day ...ay develop psychological disorders, says a study t...s. // Francisca Lopez Torrecillas, a lecturer at t...chological assessment and treatment of the Univers...
...ian belief and knowledge are great healers and 140...rently in Delhi to study this value system. // "Th...tal role in dealing with mental health issues and ...re about it," said Patrick Bantman, a psychiatrist...
...en aiming to shed after-pregnancy pounds should ad...cording to a new study by Harvard researchers. // ...isk for weight gain in women,” said lead author Em...n that early postpartum period — such as diet, tel...
Other Medicine News:Health News:Mobile Phone Addiction may Cause Psychological Problems 2Health News:Simple Solutions to Postpartum Weight Retention 2
Spinal Concepts has developed a versatile set of instruments intended to make posterior lumbar interbody fusion procedures precise, simple and quick every time. The Harmony PLIF Instrument Set is the
Kerrison (Spurling) Laminectomy Rongeur. 15 cm - 6, thick footplate, large handle, 90 up-cutting, 2 mm wide.
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide.
OSV II Smart ValveTM, Hakim, H-V Lumbar Valve system is the intelligent choice for meeting the complex demands of hydrocephalus shunting. Automatic pressure response causes the valve to adjust automa
Medicine Products: